MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium

MONTCLAIR, N.J., Dec. 4, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that John S. Condeelis, Ph.D., Chairman of MetaStat's Scientific Advisory Board, and Joan Jones, M.D., a member of MetaStat's Clinical Advisory Board, will be presenting data on the Company's licensed metastatic breast cancer markers at the CTRC-AACR 2012 San Antonio Breast Cancer Symposium on December 4-8, 2012, in San Antonio, Texas.

About MetaStat, Inc.

MetaStat was formed to help cancer patients benefit from recent discoveries in how cancer spreads through the bloodstream to other organs in the body in a process called metastasis. We believe our MetaSite Breast™ and MenaCalc™ diagnostic product lines will accurately predict the probability of cancer metastasizing. They are intended to allow clinicians to better "customize" cancer treatment decisions by positively identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and/or radiation therapies. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year. As such, we believe our diagnostic products represent a significant breakthrough for cancer patients and their doctors because 90% of all solid tumor cancer deaths are due from metastasis.

Additionally, we believe our MenaBloc™ technology provides us with targets of intervention in key pathways for the development of targeted therapeutics that may preemptively reduce or eliminate metastasis in these tumor types.

Our technology platform(s) and corresponding products are the result of over 15 years of collaboration involving four scientific/academic institutions. We believe we are unique and differentiated in the marketplace. Our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo, which enabled us to specifically isolate and thus characterize the behavior, genetics and mechanics of these highly metastatic cells.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Contact:
For More Information,
Warren C. Lau
President & CEO
MetaStat, Inc.
(973) 744-7618
[ warren@metastat.com ]

SOURCE MetaStat, Inc.

Contributing Sources

Market Wire

N@N

MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium